Teva is the world's largest generic drug manufacturer by volume and has been executing a multi-year restructuring under CEO Richard Francis to stabilise leverage and rebuild its branded pipeline. The opioid litigation settlement is behind it, removing the major legal overhang. AUSTEDO (tardive dyskinesia) is a durable branded asset growing strongly. The generics business, while low-margin, benefits from FDA prioritisation of generic approvals. De-leveraging from >6x to ~3x net debt/EBITDA is the equity re-rating catalyst.
Thesis reviewed May 29, 2026
Teva Pharmaceutical Industries Ltd. is headquartered in Israel, which is currently showing moderate signals.
🇮🇱Israel60NEUTRALView Israel risk detail →🏥Healthcare35NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| CI | The Cigna Group | 38 | +9% | ↓3% | NEUTRAL |
| HCA | HCA Healthcare Inc. | 38 | +9% | ↓3% | EARLY |
| TMO | Thermo Fisher Scientific Inc. | 38 | +11% | ↓3% | EARLY |
| ELV | Elevance Health Inc. | 38 | +7% | ↓3% | NEUTRAL |
| UNH | UnitedHealth Group Inc. | 37 | +16% | ↓3% | AVOID |
| CVS | CVS Health Corporation | 34 | +15% | ↓3% | AVOID |
| SYK | Stryker Corporation | 32 | +15% | ↓3% | EARLY |
Investors who hold TEVA may also have indirect exposure through these country funds.
AUSTEDO net revenue +28% YoY; 2026 guidance raised to $1.8B
Teva completes $3.5B opioid settlement payment; litigation overhang removed
Biosimilar pipeline: 5 launches planned for 2026 in US market
Estimates · Yahoo Finance · Not audited figures